Neurocrine Biosciences Inc vs J M Smucker Co — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while J M Smucker Co trades at $112.69 (market cap $11.97B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and J M Smucker Co pays a 3.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SJM | |
|---|---|---|
Market Cap | $17.40B | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $180.55 | $117.05 |
52-Week Low | $123.10 | $89.53 |
Enterprise Value | $16.49B | $19.00B |
Dividend Yield | — | 3.93% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →